← Oncology Approval Tracker

FDA DECISION ·

Tabrecta

capmatinib · Novartis

Traditional approvalTraditional conversionNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with metastatic NSCLC and a mutation causing MET exon 14 skipping, confirmed using an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

FDA converted the existing biomarker-defined accelerated approval to traditional approval.

What research teams should watch

Preserve the original decision date in historical reporting and keep the MET exon-skipping result distinct from other MET alterations.

PRIMARY RECORDS

Sources